Diarrhea Predominant Irritable Bowel Syndrome in Females
Diarrhea Predominant Irritable Bowel Syndrome in Females
Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS)

 The purpose of this study is to investigate the safety and effectiveness of a new
 investigational drug in women for the treatment of diarrhea-predominant irritable bowel
 syndrome. The investigational drug is a natural product taken from a plant that grows in
 South America. The study medication will be administered orally twice a day. Subjects will be
 not able to remain on certain standard IBS medications (anti-diarrheals) while participating
 in the study. The total duration of the study is 18 weeks.

 The study requires five study visits that include physical exams, ECG, blood draws,
 laboratory studies, and a colon procedure (such as a colonoscopy or flexible sigmoidoscopy if
 an appropriate procedure has not been performed in the last 5 years.) Participants will be
 asked to make entries into a touch-tone telephone diary on a daily basis.

 Participants must meet all of the following criteria:

 -  Females at least 18 years of age

 -  Diagnosis of diarrhea predominant Irritable Bowel Syndrome

 -  Willingness to make daily calls on a touch-tone telephone

 -  Willingness to have an endoscopic and/or radiologic bowel evaluation, if you have not
 received one in the past 5 years.

 -  Willingness to take an approved method of birth control (if required)

 Participants CANNOT meet any of the following criteria:

 -  Serious medical or surgical conditions

 -  Colon Cancer, Crohns Disease or Ulcerative Colitis

 -  Pregnant or breast feeding
Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS)

 The purpose of this study is to investigate the safety and effectiveness of a new
 investigational drug in women for the treatment of diarrhea-predominant irritable bowel
 syndrome. The investigational drug is a natural product taken from a plant that grows in
 South America. The study medication will be administered orally twice a day. Subjects will be
 not able to remain on certain standard IBS medications (anti-diarrheals) while participating
 in the study. The total duration of the study is 18 weeks.

 The study requires five study visits that include physical exams, ECG, blood draws,
 laboratory studies, and a colon procedure (such as a colonoscopy or flexible sigmoidoscopy if
 an appropriate procedure has not been performed in the last 5 years.) Participants will be
 asked to make entries into a touch-tone telephone diary on a daily basis.

 Participants must meet all of the following criteria:

 -  Females at least 18 years of age

 -  Diagnosis of diarrhea predominant Irritable Bowel Syndrome

 -  Willingness to make daily calls on a touch-tone telephone

 -  Willingness to have an endoscopic and/or radiologic bowel evaluation, if you have not
 received one in the past 5 years.

 -  Willingness to take an approved method of birth control (if required)

 Participants CANNOT meet any of the following criteria:

 -  Serious medical or surgical conditions

 -  Colon Cancer, Crohns Disease or Ulcerative Colitis

 -  Pregnant or breast feeding
Inclusion Criteria:

 -  Females at least 18 years of age

 -  Diagnosis of diarrhea predominant Irritable Bowel Syndrome

 -  Willingness to make daily calls on a touch-tone telephone

 -  Willingness to have an endoscopic and/or radiologic bowel evaluation, if you have not
 received one in the past 5 years.

 -  Willingness to take an approved method of birth control (if required)

 Exclusion Criteria:

 -  Serious medical or surgical conditions

 -  Colon Cancer, Crohns Disease or Ulcerative Colitis

 -  Pregnant or breast feeding